

## Product datasheet

# Human Folate Binding Protein/FBP peptide ab87124

### Description

---

<b>Product name</b>	Human Folate Binding Protein/FBP peptide
<b>Purity</b>	70 - 90% by HPLC.
<b>Animal free</b>	No
<b>Nature</b>	Synthetic
<b>Species</b>	Human

### Specifications

---

Our [Abpromise guarantee](#) covers the use of **ab87124** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

**Form** Liquid

**Additional notes**

- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn't dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

Previously labelled as Folate Binding Protein

### Preparation and Storage

---

**Stability and Storage** Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.  
Information available upon request.

### General Info

---

<b>Function</b>	Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells.
<b>Tissue specificity</b>	Exclusively expressed in tissues of epithelial origin. Expression is increased in malignant tissues. Expressed in kidney, lung and cerebellum.
<b>Involvement in disease</b>	Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD) [MIM:613068]. NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life. Onset is apparent in late infancy with severe developmental regression, movement disturbances, epilepsy, and leukodystrophy. Note=Recognition and diagnosis of this disorder is critical because folinic acid therapy can reverse the clinical symptoms and improve brain abnormalities and function.
<b>Sequence similarities</b>	Belongs to the folate receptor family.
<b>Post-translational modifications</b>	Eight disulfide bonds are present. The secreted form is derived from the membrane-bound form either by cleavage of the GPI anchor, or/and by proteolysis catalyzed by a metalloprotease.
<b>Cellular localization</b>	Cell membrane. Secreted.

**Please note:** All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

### **Our Abpromise to you: Quality guaranteed and expert technical support**

---

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

### **Terms and conditions**

---

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors